Lilly’s oral GLP‑1 wins FDA approval
Eli Lilly’s oral GLP‑1 obesity pill, orforglipron, received FDA approval and is notable for having no food or water restrictions, a feature that could ease patient use. The drug is being compared favorably in early reports against oral semaglutide for A1C and weight loss, Lilly plans international filings, and the company is also introducing a multi‑dose delivery pen for related therapies. (ajmc.com) (managedhealthcareexecutive.com) (pharmtech.com)
The Food and Drug Administration approved Eli Lilly’s obesity pill orforglipron on April 1, giving patients a once-daily glucagon-like peptide-1 tablet called Foundayo. (fda.gov) Foundayo is cleared for adults with obesity, or adults who are overweight and have at least one weight-related condition, alongside diet and exercise. The Food and Drug Administration said the review took 50 days after filing, 294 days ahead of the original January 20, 2027 target date. (fda.gov) Glucagon-like peptide-1 drugs copy a gut hormone that helps people feel fuller and eat less. Lilly’s pill is taken once a day by mouth, with or without food, and the label says patients do not need an empty stomach. (accessdata.fda.gov) That dosing detail separates it from oral semaglutide, the Novo Nordisk pill approved in December 2025 for weight loss, which entered the market as the first oral glucagon-like peptide-1 obesity drug. Eli Lilly’s approval ends Novo Nordisk’s brief run as the only company with an oral glucagon-like peptide-1 obesity treatment in the United States. (ajmc.com) (fiercepharma.com) The approved label starts patients at 0.8 milligrams daily, then steps up to 2.5 milligrams after at least 30 days and 5.5 milligrams after another 30 days. Doctors can raise the dose further to 9 milligrams, 14.5 milligrams, or 17.2 milligrams, with 17.2 milligrams as the maximum. (accessdata.fda.gov) The approval was backed by Lilly’s Phase 3 ATTAIN studies, which enrolled more than 4,500 people with obesity or overweight across two late-stage trials. Lilly said people on the highest dose who stayed on treatment in ATTAIN-1 lost an average 27.3 pounds, or 12.4% of body weight, at 72 weeks. (prnewswire.com) In ATTAIN-2, which studied adults with obesity or overweight and type 2 diabetes, Lilly said all three tested doses met the main weight-loss endpoint and key secondary goals, including reductions in hemoglobin A1C, the three-month blood sugar measure used to track diabetes. Lilly said in August 2025 that those results would support global regulatory filings. (prnewswire.com) The safety warnings look familiar to anyone who has followed this drug class. Foundayo carries a boxed warning about thyroid C-cell tumors, is contraindicated for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and the label warns about pancreatitis and severe gastrointestinal reactions. (accessdata.fda.gov) Lilly is also changing how it sells obesity medicines already on the market. In February 2026, the company introduced a four-dose KwikPen version of tirzepatide, sold as Zepbound, a format aimed at delivering a full month of weekly doses in one pen and easing device-supply pressure. (pharmtech.com) The result is a broader obesity lineup from Lilly: a new daily pill for people who want to avoid injections, and a new pen format for patients already using weekly shots. The next test is whether doctors, insurers, and pharmacies treat easier dosing as enough to widen access beyond the people already getting glucagon-like peptide-1 drugs. (fda.gov) (pharmtech.com)
